Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine added to AC/docetaxel neoadjuvant chemotherapy for large or locally advanced breast cancer
ISRCTN00407556Phase 2Completed
- Sponsor
- United Lincolnshire Teaching Hospitals NHS Trust
- Start
- Nov 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of capecitabine, doxorubicin, cyclophosphamide, docetaxel and lenograstim in breast cancer (4 arms), sponsored by United Lincolnshire Teaching Hospitals NHS Trust. Primary endpoint: Pathological response in breast and axilla. Started Nov 2008; status: completed.
02
Drugs
capecitabinedoxorubicincyclophosphamidedocetaxellenograstim
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN00407556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN00407556.